Dariush Mozaffarian
Dariush Mozaffarian
Trevor W Reichman,James F Markmann,Jon Odorico et al.
Trevor W Reichman et al.
Background: Zimislecel is an allogeneic stem cell-derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. ...
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer [0.03%]
局部晚期头颈鳞癌患者中派姆单抗新辅助和辅助治疗的临床研究
Ravindra Uppaluri,Robert I Haddad,Yungan Tao et al.
Ravindra Uppaluri et al.
Background: The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear. ...
Revised Recommendations for Covid-19 Vaccines - U.S. Vaccination Policy under Threat [0.03%]
关于新冠疫苗的最新建议——美国的疫苗政策受到威胁
Jason L Schwartz
Jason L Schwartz
Thomas J Hwang,Nancy L Keating,Stacie B Dusetzina
Thomas J Hwang
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis. Reply [0.03%]
关于左氧氟沙星预防耐多药结核病的回复
Anneke C Hesseling,H Simon Schaaf,Susan E Purchase
Anneke C Hesseling
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis. Reply [0.03%]
关于左氧氟沙星预防耐多药结核病的回复
Greg J Fox,Nguyen Viet Nhung,Guy B Marks
Greg J Fox
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis [0.03%]
左氧氟沙星预防多药耐药结核病的效果：一项开放标签随机试验
Mao-Shui Wang
Mao-Shui Wang
Ronald Lubelchek
Ronald Lubelchek
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis [0.03%]
左氧氟沙星预防耐多药结核病的效果及安全性：一项随机开放标签试验
Saul Malozowski
Saul Malozowski